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Received 26 September 2014; accepted 17 November 2014AbstractHearing loss is one of the most common birth defects, with inherited genetic defects play an important role, contributing to about 60% of
deafness occurring in infants. However, hearing impairment is genetically heterogeneous, with both common and rare forms occurring due to
mutations in estimated 500 genes. Due to the large number and presumably low mutation frequencies of those genes, it would be highly
expensive and time-consuming to address this issue by conventional gene-by-gene Sanger sequencing. Next-generation sequencing is a revo-
lutionary technology that allows the simultaneous screening of mutations in a large number of genes. It is cost effective compared to classical
strategies of linkage analysis and direct sequencing when the number or size of genes is large, and thus has become a highly efficient strategy for
identifying novel causative genes and mutations involved in heritable disease.
In this review, we describe major NGS methodologies currently used for genetic disorders and highlight applications of these technologies in
studies of molecular diagnosis and the discovery of genes implicated in non-syndromic hearing loss.
Copyright © 2015, PLA General Hospital Department of Otolaryngology Head and Neck Surgery. Production and hosting by Elsevier
(Singapore) Pte Ltd. All rights reserved.
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Identifying the genetic basis of deafness provides important
information for diagnosis, intervention and treatment of
the disease. Non-syndromic hearing loss (NSHL) is
extremely heterogeneous. To date, more than 100 genes and
100 genetic loci have been implicated in NSHL (http://
hereditaryhearingloss.org/). The marked heterogeneity of ge-
netic hearing loss can be explained by the complexity of the* Corresponding author. Department of Otolaryngology, Head and Neck
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Ltd. All rights reserved.auditory system, which requires coordination of multiple
processes involving the inner ear and nervous system. A defect
in any part of this complex chain of events can lead to hearing
impairment. For many decades, linkage analysis has been the
most powerful and widely used strategy to identify the gene
defects responsible for inherited disorders. However, this
approach is time consuming and requires the availability of
cohorts of homogeneous and informative large families, and a
large proportion of NSHL remain genetically unexplained.
These limitations, however, may be overcome by the next-
generation sequencing (NGS) technologies.
NGS offers an unprecedented ability to identify rare vari-
ants and new causative genes. Several next generation
sequencing platforms allow for a DNA-to-diagnosis protocol
to identify the molecular basis of inherited non-syndromic
hearing loss, including whole genome sequencing (WGS),y Head and Neck Surgery. Production and hosting by Elsevier (Singapore) Pte
123X. Gao, P. Dai / Journal of Otology 9 (2014) 122e125whole exome sequencing (WES) and targeted deafness gene
capture.
Updated guidelines from the American College of Medical
Genetics and Genomics (ACMG) recommend that clinicians
consider NGS when testing for genetic causes of hearing loss
(Levenson, 2014). The guidelines, which are built on guide-
lines issued in 2002, include panel tests targeted at genes
related to hearing loss, whole exome sequencing, and whole
genome sequencing after negative results are returned on
initial single-gene testing indicated by a patient's family
medical history and presentation.1.1. Whole genome sequencingTable 1
List of genes and mutations related with non-syndromic hearing loss identified
by WES.
Gene name Mutation (protein) Reference
OSBPL2 p.Gln53Argfs*100
p.Leu195Met
Xing et al. (2014)
TBC1D24 p.Ser178Leu Azaiez et al. (2014)
TNC p. Thr 1796Ser
p.V1773M
Zhao et al. (2013)
ELMOD3 p.Leu265Ser Jaworek et al. (2013)
KARS p.Asp377Asn
p.Tyr173His
Santos-Cortez et al. (2013)
GRXCR2 c.714dupT Imtiaz et al. (2014)
ATP1A2 p.Val191Met Oh et al. (2014)
ADCY1 p.Arg1038X Santos-Cortez et al. (2014)
BDP1 p.*2625Gluext*11 Girotto et al. (2013)
EPS8 p.Gln30* Behlouli et al. (2014)
PNKP p.Gly292Arg Nakashima et al. (2014)
PCDH15 p.Met65Ile
p.Ser404Arg
Nakashima et al. (2014)
CDH23 p.Pro240Leu
p.Glu1595Lys
p.Asn342Ser
Woo et al. (2014)
POU4F3 p.Arg326Lys Kim et al. (2013)
MYO15A p.Ser1481 Pro
p.Gln1425X
p.Ala1551Asp
IVS11 þ 1
p.Arg2146Q
Diaz-Horta et al. (2012);
Gao et al. (2013a);
Woo et al. (2013)
TMC1 p.Ser530X
p.Gly197Arg
p.Gln391X
Diaz-Horta et al. (2012);
Gao et al. (2013b)Whole genome sequencing (WGS) by next generation
sequencing technologies has the potential for simultaneous,
comprehensive, differential diagnostic testing of likely
monogenic illnesses. In 2003, the cost of sequencing a single
human genome was estimated to be 2.7 billion dollars, that
price had dropped to 4000 dollars by 2012, and it is antici-
pated that this cost will soon be 1000 dollars. Clinical use of
WGS by NGS has taken at least a month. It's now possible to
complete sample collection, sequencing, and analysis in less
than 50 h (Saunders et al., 2012). As this pace, WGS will be
increasingly integrated into clinical care. Researchers already
have been able to help clinicians aid some children born with
rare birth defects by sequencing and analyzing their whole
genomes to diagnose and treat their illness (Saunders et al.,
2012). WGS data are also used to advance personalized
medicine, including predicting an individual's risk of a hearing
loss attack or determining the best dosage of medication for an
individual patient. This is only the beginning of the whole
genome sequencing era, which has the potential to revolu-
tionize medicine.
However, there is no report about application of whole
genome sequencing in inherited non-syndromic hearing loss.
There are major obstacles to the clinical implementation of
WGS, such as hidden costs, issues surrounding sequencing
and analysis, quality assurance, standardization of protocols,
ethical dilemmas, and difficulties with interpretation of the
results. With the availability of human WGS data from many
individuals, it is now clear that two unrelated individuals have
at least two million differences in their genomic DNA se-
quences (Moore et al., 2011). WGS requires the analysis of
~3.2  109 bps of DNA sequences. The full potential of WGS
can be realized only when we gain a much better under-
standing of functions in noncoding regions. WGS should be
carefully implemented in the clinic to allow the realization of
its potential to improve patient health in specific indications.ACTG1 p.Met305Thr Park et al. (2013)
LOXHD1 p. Arg1494X Diaz-Horta et al. (2012)1.2. Whole exome sequencing
p. Glu955X
GIPC3 p.His170Asn Diaz-Horta et al. (2012)
ILDR1 p. Gln 274X Diaz-Horta et al. (2012)
MYO7A p.Gly2163 Ser Diaz-Horta et al. (2012)
TECTA p. Tyr 1737Cys Diaz-Horta et al. (2012)
TMPRSS3 p.F13Lfs*10 Diaz-Horta et al. (2012)
TRIOBP p. Arg785 Ser fs*50 Diaz-Horta et al. (2012)Most Mendelian disorders are caused by exonic or splice-
site mutations that alter the amino acid sequence from the
affected gene. An effective compromise between the
competing goals of genome-wide comprehensiveness and
cost-control is realized in the concept of Whole exomesequencing (WES) (Ng et al., 2009). Approximately 85% of
disease-related mutations in Mendelian disorders have been
found in the protein-coding region, although this portion
constitutes only approximately 1% of the human genome
(Teer and Mullikin, 2010). WES has become a highly efficient
strategy for identifying novel causative genes and mutations
involved in heritable disease.
Over 1778 publications since 2009, whose abstracts contain
the term “whole exome sequencing”, confirm the success of
exome sequencing as a new and effective technological
paradigm within human genetics. Exome sequencing has
proven useful for identifying molecular defects underlying
single gene disorders (Mendelian inheritance), as well as some
genetically heterogeneous disorders, such as inherited non-
syndromic hearing loss.
Inherited non-syndromic hearing loss can be resolved
efficiently using WES, especially in small families with
distinct and interesting phenotypes that were once too small to
map using linkage analysis. Recently, there have been many
successful applications of WES in identifying the causative
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(Table 1).
To date, 10 non-syndromic deafness genes and more than
30 novel causative mutations have been identified by WES
(Table 1). These studies show that WES, followed by verifi-
cation and functional and immunolabeling examinations, can
reveal critical disease-causing genes from small pedigrees.
Even with the rapid maturation of this field, there are a
number of areas that require additional work: (1) WES fails to
solve a substantial proportion of presumably Mendelian phe-
notypes (Fairfield et al., 2011). (2) There is tremendous in-
terests in understanding the contribution of rare variations to
the genetic basis of common diseases. Many such studies have
been initiated using WES, but are still ongoing as they require
additional samples to testify the results. (3) The discrete pri-
oritization of protein-altering variations over all other varia-
tions has clearly proven to be useful, but is undeniably crude.1.3. Targeted deafness gene capture and NGSThe popular application of targeted gene capture can be
implemented for all of the genes involved in causing hearing
loss, including all exons, exon/intron boundaries and promoter
sequences that can be fully sequenced on a diagnostic platform
to produce a specific genetic test for hearing loss. Targeted
deafness gene capture combined with NGS is suited to identify
the causative mutations of non-syndromic hereditary hearing
loss owing to the following advantages: 1) comprehensive
coverage of large numbers of genes and large genes associated
with the disease; 2) significant cost saving; 3) higher
sequencing accuracy because of deeper achievable coverage;
4) a significantly shorter turnaround time and 5) more
convincing dataset by excluding other deafness genes (Lin
et al., 2012).
To date, more than 100 human genes implicated in non-
syndromic hearing loss are confirmed (Lin et al., 2012).
Approximately 100 Gbp of sequencing is needed to obtain
NGS results for one human genome (~3.2 Gbp) at about 30
average coverage. Targeted gene enrichment typically in-
creases this proportion by at least 1000 fold (Brownstein et al.,
2011; Shearer et al., 2010; Tang et al., 2012). Therefore, the
same sequencing capacity can theoretically be used to
sequence more than 1000 samples for a panel of genes asso-
ciated with deafness.
Recent studies have demonstrated the feasibility of con-
ducting diagnostic tests for all deafness genes by targeted gene
capture and NGS (Brownstein et al., 2011; Shearer et al.,
2010). Its success in research has already resulted in its
translational uses in clinical care, and many of them are for
diagnostic mutation detection of focused panels of disease
genes. OtoSCOPE (Otological Sequence Capture Of Patho-
genic Exons) is the first massively parallel sequencing plat-
form that utilizes targeted sequence capture and NGS for
genetic testing of hearing loss (Shearer et al., 2010). It has
been developed by the University of Iowa and is being used in
a research setting to fully sequence all exons of 57 deafness
genes (http://www.healthcare.uiowa.edu/labs/morl/index_CDS.htm). At this stage in its development various methods
of targeted sequence capture and NGS are being compared to
determine which combination has the greatest level of
sequence coverage. Otogenetics Corporation in the USA is
currently offering a genetic mutation testing service using
targeted sequence capture and NGS for the detection of vari-
ants in 131 known deafness genes for approximately $500 per
sample (www.otogenetics.com).
Richard J.H. Smith, MD, Director of the Molecular
Otolaryngology and Renal Research Laboratories at the Iowa
Institute of Human Genetics at University of Iowa in Iowa
City, is a proponent of panel testing for hearing loss. His lab
offers a test that covers 90 genes known to cause hearing loss,
which he suggests over any initial single-gene test. Because
panel tests offer more depth of coverage in genes associated
with hearing loss, they are superior to WES at some extent,
which looks at 20,000 genes and may miss parts of them.
If single-gene tests yield no diagnosis, panel tests is rec-
ommended. The drawbacks of panel tests are these tests,
which use disease-targeted exon capture focused on specific
genes, may only sequence a subset of the genes known to
cause hearing loss, and there is limited knowledge of which
genes are involved in hearing loss.1.4. Challenge and futureIt is anticipated that the next five to ten years will see yet
more improvements in the speed and cost of DNA sequencing.
There is already discussion about “third generation” DNA
sequencing, which aims to increase the speed of sequencing
and reduce cost even further.
Applications of NGS technologies are now beginning to
enter clinical practice. Interpreting the data and translating the
research results into applications that improve healthcare is
still challenging. Filtering through the millions of variants in
an individual's genome for the pathogenic mutation seems to
be the most urgent task at hand. Another important aspect is
the concurrent development of genetic counseling capabilities
to interpret the large amount of data revealed by NGS for
clinical use. In the near future, physicians may combine a past
medical history and family history with NGS diagnostic data
to identify disease predisposition variants and variants that
affect drug metabolism in individuals.
Although NGS-based molecular diagnostic tests are still in
their infancy, they have demonstrated excellent clinical utility
for single-gene disorders. With further developments in NGS
technologies for data generation and with more effective
bioinformatics tools for data analysis and clinical extraction,
the full potential of WES/WGS that we expect to be revealed
in the coming years will greatly enrich and empower the
practice of genomic medicine beyond the rare single-gene
disorders. The improvements in patient care demonstrated in
recent studies justify all effort and cost for moving these new
and exciting approaches into molecular diagnostics practice.
In our opinion, WES, WGS and targeted deafness gene
capture should remain as options to be considered for inherited
non-syndromic hearing loss and be used according to a
125X. Gao, P. Dai / Journal of Otology 9 (2014) 122e125patient's specific conditions. Alternatively, a combined
approach can be used to capture all variety of genomic
variations.
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